| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
|
| Targets |
β-lactam
|
|---|---|
| ln Vitro |
On lipopolysaccharide-stimulated C8-B4 cells, cefazolin (0-300 μg/mL; 6 or 24 h) exhibits a direct anti-inflammatory action [2]. Treatment with cefazolin (0-400 μM; 72 h) decreases the growth of cells stimulated by IL-2, IL-4, and IL-15 [3]. Treatment with cefazolin (100–400 μM; 30 min) prevents JAK3 phosphorylation in response to IL-2, IL-4, IL-15, and IL-21 stimulation [3]. Cefazolin
|
| ln Vivo |
Following surgery, mice treated with cefazolin sodium pentahydrate (subcutaneous injection; 300–500 mg/kg; once daily; 5 d) have improved learning and memory [2].
|
| Cell Assay |
Cell Viability Assay[2]
Cell Types: C8-B4 cells Tested Concentrations: 0, 50, 100, 150, 200, 250, or 300 μg/ml Incubation Duration: 6 or 24 hrs (hours) Experimental Results: Inhibited the increase of IL-1β at all doses, but inhibited the increase of IL-6 only at 200 μg/ml. Cell Proliferation Assay[3] Cell Types: PBMC, and TF-1 cells Tested Concentrations: 0, 100, 200, and 400 μM Incubation Duration: 72 hrs (hours) Experimental Results: decreased IL-2, IL-4 and IL-15-induced cell proliferation, suggested that Cefazolin interferes not only with IL-15Rα, but also with IL-2/IL-15Rβ and/or γc. Cell Proliferation Assay[3] Cell Types: PBMC, NK-92, and TF-1 cells Tested Concentrations: 0, 100, 200, and 400 μM Incubation Duration: 30 min Experimental Results: Diminished the phosphorylation of JAK3 in response to the cytokine treatment, concluded suppressing signal transduction by γc receptors. |
| Animal Protocol |
Animal/Disease Models: 6- to 8weeks old male CD-1 mice underwent clinical exploratory laparotomy[2]
Doses: 300-500 mg/kg Route of Administration: subcutaneous (sc)injection; 300-500 mg/kg; one time/day; 5 days Experimental Results: Attenuated learning and memory dysfunction induced by the surgery. |
| References |
[1]. R Quintiliani, et al. Cefazolin. Ann Intern Med. 1978 Nov;89(5 Pt 1):650-6.
[2]. Peng Liang, et al. Perioperative use of cefazolin ameliorates postoperative cognitive dysfunction but induces gut inflammation in mice. J Neuroinflammation. 2018 Aug 22;15(1):235. [3]. Barbara Żyżyńska-Granica, et al. The anti-inflammatory potential of cefazolin as common gamma chain cytokine inhibitor. Sci Rep. 2020 Feb 19;10(1):2886. |
| Molecular Formula |
C14H14N8O4S3
|
|---|---|
| Molecular Weight |
454.51
|
| CAS # |
25953-19-9
|
| Related CAS # |
Cefazolin sodium;27164-46-1;Cefazolin sodium pentahydrate;115850-11-8
|
| SMILES |
O=C(C(N12)=C(CSC3=NN=C(C)S3)CS[C@]2([H])[C@H](NC(CN4N=NN=C4)=O)C1=O)O
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 250 mg/mL (550.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.58 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.58 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.58 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2002 mL | 11.0009 mL | 22.0017 mL | |
| 5 mM | 0.4400 mL | 2.2002 mL | 4.4003 mL | |
| 10 mM | 0.2200 mL | 1.1001 mL | 2.2002 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
